We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

66 hedge funds and large institutions have $27.4M invested in Matinas BioPharma in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 0.24% → 0.25% (+0.01%)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

1% less funds holding

Funds holding: 67 → 66 (-1)

18% less capital invested

Capital invested by funds: $33.5M → $27.4M (-$6.11M)

Holders
66
Holders Change
-1
Holders Change %
-1.49%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
12
Reduced
13
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.68M
2
SIG
Sargent Investment Group
Maryland
+$410K
3
CCM
Courage Capital Management
Tennessee
+$214K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$205K
5
SWM
Spire Wealth Management
Virginia
+$169K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$967K
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$221K
3
Jane Street
Jane Street
New York
-$211K
4
VF
Virtu Financial
New York
-$156K
5
PAG
Private Advisor Group
New Jersey
-$75.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
51
Clarus Group
Texas
$13K – – –
AWM
52
AE Wealth Management
Kansas
$12K +$12.7K +238 New
JWCA
53
J.W. Cole Advisors
Florida
$11K – – –
BJL
54
Brighton Jones LLC
Washington
$10K – – –
CFS
55
CRA Financial Services
New Jersey
$10K – – –
FAIM
56
Financial Advocates Investment Management
Washington
$10K – – –
FC
57
Fore Capital
New York
$10K – – –
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
$7K -$6.74K -126 -47%
MIFH
59
Migdal Insurance & Financial Holdings
Israel
$6K -$3.74K -70 -37%
HFM
60
Hartford Financial Management
Connecticut
$3K – – –
SPIA
61
Steward Partners Investment Advisory
New York
$3K – – –
IA
62
IFP Advisors
Florida
$2K – – –
GWMIA
63
Global Wealth Management Investment Advisory
Florida
$1K – – –
HR
64
Howe & Rusling
New York
$1K – – –
GCP
65
GSA Capital Partners
United Kingdom
– -$967K -14,880 Closed
T. Rowe Price Associates
66
T. Rowe Price Associates
Maryland
– -$221K -3,396 Closed
Jane Street
67
Jane Street
New York
– -$211K -3,243 Closed
TRCT
68
Tower Research Capital (TRC)
New York
– -$60K -919 Closed
WG
69
Winton Group
United Kingdom
– -$41K -634 Closed
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$25K -379 Closed
OIA
71
OneDigital Investment Advisors
Kansas
– -$23K -360 Closed
PCM
72
Perkins Capital Management
Minnesota
– -$19K -290 Closed
UBS Group
73
UBS Group
Switzerland
– -$13K -206 Closed
AAS
74
Avantax Advisory Services
Texas
– -$13K -200 Closed
EWM
75
Endurance Wealth Management
Rhode Island
– -$9K -135 Closed
1 2
3
4

MTNB Hedge Fund Activity: Q4 2021 in Review

66 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2021, worth a combined $27.4M — down 18% from $33.5M a quarter earlier.

Fund positioning in MTNB was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 12 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $1.68M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $967K sold.

  • 66 institutional investors held Matinas BioPharma (MTNB) as of Q4 2021, down from 67 in Q3 2021.
  • Funds reported $27.4M of Matinas BioPharma stock for Q4 2021, down 18% quarter-over-quarter.
  • 11 funds opened new Matinas BioPharma positions in Q4 2021 and 11 closed out, a net change of 0 holders.
  • The largest Matinas BioPharma buyer in Q4 2021 was BlackRock, an estimated $1.68M added.
  • The largest Matinas BioPharma seller in Q4 2021 was GSA Capital Partners, an estimated $967K sold.

Based on aggregated 13F filings for Q4 2021.